Navigation Links
London Genetics Expands its Senior Advisory Team
Date:7/22/2010

LONDON, July 22, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that it has augmented the strength of its team with the appointment of two senior advisers, Professors Stephen DeCherney and Munir Pirmohamed. With their extensive clinical, healthcare, and drug development expertise, their guidance will be invaluable to London Genetics.

Stephen DeCherney MD, MPH, is Professor of Medicine at the University of Carolina, and was previously President, Global Clinical Organisation and Chief Innovation Officer at Quintiles Transnational Corporation. With research interests in internal medicine, endocrinology and diabetes, Professor DeCherney spent five years at the US National Institutes of Health, followed by various management roles at the Christiana Care Health System in Delaware, where he was principal investigator in more than 100 clinical trials. He is on the Board of Certara, Inc and has an MPH from Columbia University School of Public Health.

As holder of the NHS Chair of Pharmacogenetics at the University of Liverpool, Professor Munir Pirmohamed MB, ChB (Hons), PhD, FRCP, FRCP(E) is a leading researcher in the area of pharmacogenetics and drug safety. He is involved in the European EU-PACT Phase IV study, which is looking at the effect of gene-based dosing of warfarin on 2000 patients, and is expected to provide an important indication of the value pharmacogenetics can bring to clinical practice. After qualifying in medicine, Professor Pirmohamed obtained a PhD in pharmacology, and is Deputy Director of the MRC Cent
'/>"/>

SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
2. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
3. The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program
4. Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010
5. New Appointments at London Genetics to Drive Strategy Forward
6. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
7. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
8. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
9. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
10. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
11. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Can economic incentives such as gift cards, ... the public to increase their donations of blood? , ... Business School Assistant Professor Mario Macis says the ... body of recent research that supports their argument, the ... of Science that the World Health Organization and national ...
(Date:5/23/2013)... Patheon Inc ., a leading ... global pharmaceutical industry, will host a complimentary webinar on ... on Tuesday, June 4, 2013 at 11 a.m. Eastern ... to comply with regulations for cleaning validation. Many ... underpinning and little evaluation of risk. Some companies ...
(Date:5/23/2013)...  Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., ... banking and therapeutics, announced today that StemCyte has become ... Indy car driven by James Jakes ... IndyCar 2013 season.   StemCyte, Inc. and Rahal ... of umbilical cord blood banking and its educational initiative ...
(Date:5/23/2013)... Auburn, MA (PRWEB) May 23, 2013 ... one inch wide and provide 15 mm travel ... nanometers. The small dimensions make these new ... in confined spaces. A vacuum rated version is ... Datasheet:, Drawings, specifications and datasheets can be found ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2
... OSLO, Norway, June 17 , ... Shown to Improve Remission Rates and,Reduce Short-Term Mortality Compared ... Pharma ASA (OSE: CLAVIS) today announces positive final results,from ... drug, elacytarabine,(CP-4055), in patients with late-stage acute myeloid leukaemia ...
... ... and Communications Convergence , ... San Diego, CA (PRWEB) June 17, 2009 -- CommNexus and Leap ... unlimited wireless services, today announce their support for EvoNexus, a non-profit incubator dedicated to ...
... by Advanced Cell Technology,s Chief Scientist, Robert Lanza yields answers ... 16 MSNBC.com featured today Dr. Robert Lanza,s book (co-authored ... Consciousness are the Keys to Understanding the True Nature of ... Log." The article by Science Editor Alan Boyle includes ...
Cached Biology Technology:Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 2San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 3San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 4MSNBC Publishes Free Online Abridgment of 'Biocentrism' 2MSNBC Publishes Free Online Abridgment of 'Biocentrism' 3
(Date:5/22/2013)... also conclude that the 20 percent reduction in ... versus chest X-ray (CXR) screening previously reported in ... screening centers in the United States. , Philadelphia, ... patients about the benefits and risks of LDCT ... New England Journal of Medicine of ...
(Date:5/22/2013)... major new effort to educate the public and decision ... clean water that looms ahead in the 21st century. ... current edition of Chemical & Engineering News , ... the world,s largest scientific society. , Bassam Z. Shakhashiri, ... Ph.D., explain that shortages of reliable supplies of fresh ...
(Date:5/22/2013)... health effects from disposal of millions of rechargeable ... recommend stronger government policies to encourage recovery, recycling ... the conclusion of a new paper in the ... , Oladele A. Ogunseitan and colleagues point out ... everything from smart phones to components in new ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... Launches New Multi-Modal Biometric Identification Solution ... Enhanced Performance and Interoperability, SCHAUMBURG, Ill., March ... announced that it has been selected by the ... Biometric Identification,Solution (BIS). Motorola,s latest BIS solution features ...
... a genetic variant that can protect them after heart ... at Washington University School of Medicine in St. Louis ... effect that resembles that of beta blockers, drugs widely ... reason why beta blockers don,t appear to benefit some ...
... Researchers from The University of Arizona and Columbia University ... together and pull with forces far stronger than experts ... including Magdalene Maggie So, a member of the BIO5 ... College of Medicine, studied Type IV pili or ...
Cached Biology News:Motorola Biometric Identification System Selected by West Virginia State Police 2Many African-Americans have a gene that prolongs life after heart failure 2Many African-Americans have a gene that prolongs life after heart failure 3Many African-Americans have a gene that prolongs life after heart failure 4University of Arizona scientist shares in discovery of microbe filaments' power 2
... Analysis Note: Protein determined ... in 3.2 M (NH 4 ... pH 7.0 Preparation Note: Affinity ... sulfate suspension • Additives: MgCl ...
... PP2A, purified MW: 60kDa (A) and ... 20mM MOPS, pH 7.5, 500mM NaCl, ... 0.1mM MnCl2 1mM DTT, and 0.1mg/ml ... vitro dephosphorylation of proteins. Purification: DEAE ...
... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
Selective media for Salmonella...
Biology Products: